Morphic (MORF)
Search documents
Morphic (MORF) - 2022 Q1 - Quarterly Report
2022-05-04 12:14
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13, OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38940 MORPHIC HOLDING, INC. (Exact name of registrant as specified in its charter) Delaware (State or other ...
Morphic Holding (MORF) Investor Presentation - Slideshow
2022-03-25 18:00
DELIVERING A NEW GENERATION OF INTEGRIN MEDICINES March 2022 Forward Looking Statements This presentation contains "forward-looking" statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to: Morphic's or our partners' plans to develop and commercialize oral small-molecule integrin therapeutics and Morphic's expectations about timing and ability to commence, enroll or complete clinical studies and to obtain regulatory ...
Morphic (MORF) - 2021 Q4 - Annual Report
2022-02-24 13:11
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13, OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38940 MORPHIC HOLDING, INC. (Exact name of registrant as specified in its charter) Delaware (State or other juris ...
Morphic (MORF) - 2021 Q3 - Quarterly Report
2021-11-04 20:41
☒ QUARTERLY REPORT PURSUANT TO SECTION 13, OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) 02451 (Zip Code) Registrant's telephone number, including area code: (781) 996-0955 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38940 MORPHIC HOLDIN ...
Morphic Holding (MORF) Investor Presentation - Slideshow
2021-09-10 18:14
DELIVERING A NEW GENERATION OF INTEGRIN MEDICINES September 2021 Forward Looking Statements This presentation contains "forward-looking" statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to: Morphic's or our partners' plans to develop and commercialize oral small-molecule integrin therapeutics and Morphic's expectations about timing and ability to commence, enroll or complete clinical studies and to obtain regula ...
Morphic (MORF) - 2021 Q2 - Quarterly Report
2021-08-04 11:24
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13, OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Address of Principal Executive Offices) 47-3878772 (I.R.S. Employer Identification No.) 02451 (Zip Code) Registrant's telephone number, including area code: (781) 996-095 ...
Morphic (MORF) - 2021 Q1 - Quarterly Report
2021-04-29 12:08
(Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13, OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38940 MORPHIC HOLDING, INC. (Exact name of registrant as specified in its charter) Delaware (State or other ...
Morphic (MORF) - 2020 Q4 - Earnings Call Transcript
2021-03-01 19:28
Morphic Holding, Inc. (NASDAQ:MORF) Q4 2020 Earnings Conference Call March 1, 2021 8:00 AM ET Company Participants Chris Erdman - Senior Vice President of Communications Praveen Tipirneni - Chief Executive Officer Marc Schegerin - Chief Operating Officer and Chief Financial Officer Bruce Rogers - Chief Scientific Officer Peter Linde - Chief Medical Officer Conference Call Participants Michael Yee - Jefferies Gregory Renza - RBC Capital Markets Do Kim - BMO Capital Markets Ritu Baral - Cowen Yasmeen Rahimi - ...
Morphic (MORF) - 2020 Q4 - Annual Report
2021-03-01 13:06
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ⌧ ANNUAL REPORT PURSUANT TO SECTION 13, OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38940 MORPHIC HOLDING, INC. (Exact name of registrant as specified in its charter) | Delaware | | --- | | (State ...
Morphic (MORF) - 2020 Q3 - Quarterly Report
2020-11-09 12:49
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ⌧ QUARTERLY REPORT PURSUANT TO SECTION 13, OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38940 MORPHIC HOLDING, INC. (Exact name of registrant as specified in its charter) Delaware (State or ot ...